Published works by Robert Terzoli

Published works

• Winning Combinations – Protecting Trade Secrets in Government Contracting: Risks and Safeguarding Strategies

  Claims & Sustains · July 30, 2025

  LEX-WK-DCR0PWT5
• Upcoming Webinar: Protecting Trade Secrets in Government Contracting: Risks and Safeguarding Strategies

  Claims & Sustains · July 17, 2025

  LEX-WK-A9ZZZFFX
• Webinar – Protecting Trade Secrets in Government Contracting: Risks and Safeguarding Strategies

  Trading Secrets · July 17, 2025

  LEX-WK-2GH3M8TQ
• NLRB’s Non-Compete Power Grab – Can Employers Avoid NLRB’s Oversight?

  Trading Secrets · July 18, 2024

  LEX-WK-BGCMSY3F
• U.S. Isn’t Everything – The Importance for U.S. Entities to Obtain Trademark Protection Abroad (Yes, that includes Canada)

  Gadgets, Gigabytes & Goodwill Blog · June 11, 2024

  LEX-WK-2888XQDN
• Now Available! 50 State Survey of Legal Excusability

  The Construction Seyt · June 23, 2020

  LEX-WK-TBE5E8J8
• USPTO Allows Hemp-related Trademarks on or after December 20, 2018

  The Blunt Truth® · June 11, 2019

  LEX-WK-1X5HAHRV
• Tribal Immunity Cannot Be Asserted to Escape IPR Proceedings

  BioLoquitur · July 25, 2018

  LEX-WK-TXR6A59Z
• FDA Approves First Marijuana-Based Drug to Treat Epilepsy

  BioLoquitur · July 5, 2018

  LEX-WK-Y30DQFHH
• FDA Approves First Marijuana-Based Drug to Treat Epilepsy

  The Blunt Truth® · July 5, 2018

  LEX-WK-Y3NY4K25
• An Illustrated Guide to the USPTO’s New Memo on Method of Treatment Claims

  BioLoquitur · June 29, 2018

  LEX-WK-23AE6EF6
• USPTO Announces Notice of Proposed Rulemaking for Claim Construction Standard used in PTAB Proceedings

  BioLoquitur · May 8, 2018

  LEX-WK-XGN3N2BT
• Part 2 of 2: Supreme Court and Inter Partes Review

  BioLoquitur · April 30, 2018

  LEX-WK-086RKN4T
• Part 1 of 2: Supreme Court and Inter Partes Review

  BioLoquitur · April 30, 2018

  LEX-WK-TT4T1E6Z
• Federal Circuit Opens Door for PTAB Institution Decision Appeals

  BioLoquitur · January 23, 2018

  LEX-WK-PNK9MT7P
• No Longer the Stuff of Science Fiction: The FDA’s New Policy Approach to Regenerative Medicine Products

  BioLoquitur · December 11, 2017

  LEX-WK-8TR9VZK1
• Shire v. Amneal – Compound Claim Not Obvious and API Supplier Not Liable Under FDA Safe Harbor

  BioLoquitur · October 6, 2015

  LEX-WK-V9PQ80GE
• Patent Licensors Beware – No Challenge Clause Does Not Bar Challenge Before the PTAB

  BioLoquitur · September 28, 2015

  LEX-WK-NGQWDV29
• Teaching Away Negated by References Disclosing How to Offset Disadvantages

  BioLoquitur · September 15, 2015

  LEX-WK-33AGZQNM
• For BioPharma, Citing Relevant Art During Prosecution Does Not Appear to Minimize IPR Risk

  BioLoquitur · August 31, 2015

  LEX-WK-NETEFFTD
• Does the scope of immunity from assertions of patent infringement against U.S. government contractors under 28 U.S.C. § 1498 extend to acts of indirect infringement?

  BioLoquitur · June 15, 2015

  LEX-WK-7897ZE7B